BeiGene: ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo
ImmunityBio has partnered with BeiGene for conducting the trial combining tislelizumab and Anktiva to treat advanced or metastatic NSCLC. The post ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo appeared first on Clinical Trials Arena.
Read full article »
BeiGene is a biotechnology company that develops and commercializes immunotherapeutics for the treatment of cancer.
Read more